Benjamin Kearns

1.8k total citations · 1 hit paper
45 papers, 1.3k citations indexed

About

Benjamin Kearns is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Benjamin Kearns has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Benjamin Kearns's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Colorectal Cancer Screening and Detection (8 papers) and Chronic Disease Management Strategies (6 papers). Benjamin Kearns is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Colorectal Cancer Screening and Detection (8 papers) and Chronic Disease Management Strategies (6 papers). Benjamin Kearns collaborates with scholars based in United Kingdom, Singapore and Sweden. Benjamin Kearns's co-authors include Mei Sun, Adam Pickett, Chris Smith, Andrew B. Lindstrom, Mark J. Strynar, Detlef R.U. Knappe, Michael Richardson, Christine Smith, Matt Stevenson and Clare Relton and has published in prestigious journals such as British Journal of Cancer, International Journal of Epidemiology and Human Reproduction.

In The Last Decade

Benjamin Kearns

44 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Legacy and Emerging Perfluoroalkyl Substances Are Important Drinking Water Contaminants in the Cape Fear River Watershed of North Carolina

2016 550 citations Benjamin Kearns et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Kearns United Kingdom	17	509	408	250	232	150	45	1.3k
Changchun Xie United States	33	424 0.8×	856 2.1×	82 0.3×	64 0.3×	408 2.7×	108	4.0k
Lyndsey A. Darrow United States	34	545 1.1×	2.9k 7.2×	292 1.2×	76 0.3×	218 1.5×	94	4.0k
Cathy Lally United States	29	181 0.4×	303 0.7×	28 0.1×	58 0.3×	210 1.4×	57	2.3k
Loren Lipworth United States	28	629 1.2×	1.2k 2.9×	110 0.4×	46 0.2×	273 1.8×	53	3.9k
Donald R. Taves United States	23	187 0.4×	243 0.6×	61 0.2×	130 0.6×	167 1.1×	53	3.0k
Ulla B. Mogensen Denmark	17	471 0.9×	447 1.1×	90 0.4×	17 0.1×	86 0.6×	22	1.3k
Shigeo Tomura Japan	26	137 0.3×	196 0.5×	43 0.2×	43 0.2×	209 1.4×	81	1.7k
Kirsten T. Eriksen Denmark	17	419 0.8×	577 1.4×	78 0.3×	12 0.1×	35 0.2×	29	1.1k
David B. Richardson United States	25	76 0.1×	774 1.9×	24 0.1×	59 0.3×	402 2.7×	74	2.4k
Stephanie J. Frisbee United States	24	1.3k 2.6×	1.0k 2.5×	186 0.7×	19 0.1×	367 2.4×	60	2.8k

Countries citing papers authored by Benjamin Kearns

Since Specialization

Citations

This map shows the geographic impact of Benjamin Kearns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Kearns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Kearns more than expected).

Fields of papers citing papers by Benjamin Kearns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Kearns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Kearns. The network helps show where Benjamin Kearns may publish in the future.

Co-authorship network of co-authors of Benjamin Kearns

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Kearns. A scholar is included among the top collaborators of Benjamin Kearns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Kearns. Benjamin Kearns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Woods, Beth, Dina Janković, Benjamin Kearns, et al.. (2024). Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. 28(28). 1–238. 3 indexed citations

Harnan, S, Benjamin Kearns, Alison Scope, et al.. (2024). Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. 28(73). 1–230.

Kearns, Benjamin, Katy Cooper, Martin Orr, et al.. (2022). The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric Disease and Treatment. Volume 18. 1133–1143. 10 indexed citations

Bullement, Ash & Benjamin Kearns. (2022). Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Services and Outcomes Research Methodology. 22(3). 317–331. 4 indexed citations

Kearns, Benjamin, Matt Stevenson, Kostas Triantafyllopoulos, & Andrea Manca. (2022). Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. Medical Decision Making. 42(7). 945–955. 1 indexed citations

Kearns, Benjamin, Katy Cooper, Anna Cantrell, & Chloe Thomas. (2021). Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment. Volume 17. 125–137. 13 indexed citations

Kearns, Benjamin, et al.. (2020). EX2 Structural Uncertainty in Survival Extrapolation: Exploring the IMPACT of FOUR MODEL Averaging Methods and Adjusting for DATA Maturity. Value in Health. 23. S402–S402. 2 indexed citations

Kearns, Benjamin, Matt Stevenson, Kostas Triantafyllopoulos, & Andrea Manca. (2019). Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function. Medical Decision Making. 39(7). 867–878. 32 indexed citations

Kearns, Benjamin, John Stevens, Shijie Ren, & Alan Brennan. (2019). How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. PharmacoEconomics. 38(2). 193–204. 28 indexed citations

10.

Kearns, Benjamin, John Stevens, Praveen Thokala, et al.. (2019). A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making. 39(8). 899–909. 36 indexed citations

11.

Kearns, Benjamin, J. Chilcott, Clare Relton, et al.. (2018). The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studies. Cancer Management and Research. Volume 10. 637–645. 7 indexed citations

12.

Kearns, Benjamin, Rachid Rafia, Joanna Leaviss, et al.. (2017). The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Research. 17(1). 78–78. 14 indexed citations

13.

Kearns, Benjamin & Steven Thomas. (2017). Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open. 7(1). e013460–e013460. 10 indexed citations

14.

Kearns, Benjamin, J. Chilcott, Sophie Whyte, Louise Preston, & Susannah Sadler. (2016). Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Medicine. 14(1). 200–200. 24 indexed citations

15.

Kearns, Benjamin, Sophie Whyte, Helen E. Seaman, et al.. (2016). Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. British Journal of Cancer. 114(3). 327–333. 7 indexed citations

16.

Ara, Roberta, et al.. (2014). Predicting preference-based utility values using partial proportional odds models. BMC Research Notes. 7(1). 438–438. 3 indexed citations

17.

Uttley, Lesley, Benjamin Kearns, Shijie Ren, & Matt Stevenson. (2013). Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal. PharmacoEconomics. 31(11). 981–990. 5 indexed citations

18.

Kearns, Benjamin, Myfanwy Lloyd Jones, Matt Stevenson, & Chris Littlewood. (2013). Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal. PharmacoEconomics. 31(6). 479–488. 30 indexed citations

19.

Kearns, Benjamin, Hugh Gallagher, & Simon de Lusignan. (2013). Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. BMC Nephrology. 14(1). 49–49. 28 indexed citations

20.

Kearns, Benjamin, Roberta Ara, Tracey Young, & Clare Relton. (2013). Association between body mass index and health-related quality of life, and the impact of self-reported long-term conditions – cross-sectional study from the south Yorkshire cohort dataset. BMC Public Health. 13(1). 1009–1009. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact